Abstract:Alzheimer’s disease (AD) is a tenacious neurodegenerative dementia, characterized clinically by progressive loss of memory, cognitive dysfunction, and behavioral abnormalities, accompanied by the accumulation of intracellular neurofibrillary tangles (NFTs), neuropil threads, as well as extracellular amyloid-beta containing senile plaques, cerebrovascular amyloid-beta deposits, and selective nerve cell and synapse loss (Kelliher et al, 1999; Tanzi, 1999; Solertea et al, 2000). The last two decades have witnessed an expanding body of research that elucidated the central role of amyloid precursor protein (APP) processing and amyloid beta (Abeta) production in the risk, onset, and progression of AD (Findeis, 2007). The accumulation of insoluble aggregates of Abeta peptide 1–42 (Abeta42) derived from APP is believed to play an important role in AD (Hardy, 1997; Kelliher et al, 1999). The generation of Abeta peptides requires two sequential proteolytical cleavages of APP by beta-secretase (BACE1) (Rosner et al, 2006) and gamma-secretase, composed of four integral membrane proteins, presenilins (PS1/2), APH-1 (anterior pharynx-defective 1), PEN-2 (presenilin enhancer 2) and nicastrin (NCT) (Kaether et al, 2006; Zhang & Koo, 2006). Previous evidence points to the involvement of the endoplasmic reticulum (ER) in AD pathogenesis owing to the fact that it is an important site for generating Abeta42 in neurons (Hartmann et al, 1998) and that presenilins are predominantly localized in this cellular compartment (Kovacs et al, 1996; Cook et al, 1996). Cleavage of the APP ectodomain by beta-secretase at the amino-terminus of Abeta is followed by cleavage of the beta-secretasegenerated carboxyl-terminal fragment (beta-CTF, C99) at the carboxyl terminus of Abeta  by gamma-secretase. A third activity, referred to as alpha-secretase, cleaves otherwise the APP ectodomain within the Abeta sequence, and subsequent cleavage of the alpha-secretasederived APP CTF (alpha-CTF, C83) by gamma-secretase results in production of P3

Substrate Interaction Inhibits Γ-Secretase Production of Amyloid-Β Peptides.

P4‐687: SUBSTRATE BINDING INHIBITS Γ‐secretase CLEAVAGE OF AMYLOID PRECURSOR PROTEIN

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide.

Substrate check of γ-secretase

Substrate check of gamma-secretase.

Modulation of gamma-secretase specificity using small molecule allosteric inhibitors.

Structural basis of -secretase inhibition and modulation by small molecule drugs

Construction of Drug Screening Cell Model and Application to New Compounds Interfering Production and Accumulation of Beta-Amyloid by Inhibiting Gamma-Secretase

Covalent Fragment Inhibits Intramembrane Proteolysis

Enzyme–substrate interface targeting by imidazole‐based γ‐secretase modulators activates γ‐secretase and stabilizes its interaction with APP

Inhibition of Γ-Secretase Activity Reduces Aβ Production, Reduces Oxidative Stress, Increases Mitochondrial Activity and Leads to Reduced Vulnerability to Apoptosis: Implications for the Treatment of Alzheimer's Disease

Proton myo-inositol cotransporter is a novel γ-secretase associated protein that regulates Aβ production without affecting Notch cleavage

IDENTIFICATION OF A SMALL MOLECULE INHIBITOR OF TAU AGGREGATION

Self-Assembly Molecular Chaperone to Concurrently Inhibit the Production and Aggregation of Amyloid Β Peptide Associated with Alzheimer’s Disease

Targeting Amyloidogenic Processing of APP in Alzheimer’s Disease

Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity.

Molecular Recipe for Γ-Secretase Modulation from Computational Analysis of 60 Active Compounds

Discovery of a Novel Pharmacological and Structural Class of Gamma Secretase Modulators Derived from the Extract of Actaea Racemosa.

Inhibition of Delta-Secretase Improves Cognitive Functions in Mouse Models of Alzheimer’s Disease

Soluble γ-secretase modulators selectively inhibit the production of the 42-amino acid amyloid β peptide variant and augment the production of multiple carboxy-truncated amyloid β species.